Brief: Sam Chun Dang Pharm Co European Medicines Agency Approves Phase I Clinical Study Plan On Oral Insulin In Germany
29/05/2026 02:13
BRIEF-Sam Chun Dang Pharm Co European Medicines Agency Approves Phase I Clinical Study Plan On Oral Insulin In Germany Sam Chun Dang Pharm Co Ltd 000250.KQ:
EUROPEAN MEDICINES AGENCY APPROVES PHASE I CLINICAL STUDY PLAN ON ORAL INSULIN IN GERMANY
Source text: [ID:]
Further company coverage: 000250.KQ
Recent news on Sam Chun Dang Pharm
See all newsBrief: Sam Chun Dang Pharm Co European Medicines Agency Approves Phase I Clinical Study Plan On Oral Insulin In Germany
Brief: Sam Chun Dang Pharm Co To Buy 9.9 Billion Won Worth Of Shares In Optus Pharmaceutical
Brief: Sam Chun Dang Pharm To Divest 29.5 Billion Won Worth Of Own Shares
Brief: Sam Chun Dang Pharm To Divest 61 Billion Won Worth Of Own Shares
Brief: Sam Chun Dang Pharm Wins Exclusive Sales Rights To Supply Aflibercept Biosimilar For Treatment Of Macular Degeneration In Germany, Spain, Italy, Switzerland, Austria